about
Current perspectives in bladder cancer managementVersatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental studyBladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogsIdentification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.The safety parameters of the study on intraductal cytotoxic agent delivery to the breast before mastectomyPreparation and characterization of gelatin-based mucoadhesive nanocomposites as intravesical gene delivery scaffoldsIntraperitoneal therapy for peritoneal cancer.RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancerLack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignanciesHuachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivoOptimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.Intraductal therapy of ductal carcinoma in situ: a presurgery study.Oncolytic viruses in the treatment of bladder cancerInterleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expressioImmunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies.Heterogeneity of uroplakin localization in human normal urothelium, papilloma and papillary carcinoma.Emerging intravesical therapies for management of nonmuscle invasive bladder cancerIn vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancerRole and rationale of gene therapy and other novel therapies in the management of NMIBC.Investigational therapies for non-muscle invasive bladder cancer.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Intravesical drug delivery for dysfunctional bladder.Glycan-targeted drug delivery for intravesical therapy: in the footsteps of uropathogenic bacteria.Valrubicin in refractory non-muscle invasive bladder cancer.The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.Current status of clinical trials assessing oncolytic virus therapy for urological cancers.Catalpol Inhibited the Proliferation of T24 Human Bladder Cancer Cells by Inducing Apoptosis Through the Blockade of Akt-Mediated Anti-apoptotic Signaling.Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity.Biomimetic delivery strategies at the urothelium: targeted cytoinvasion in bladder cancer cells via lectin bioconjugates.MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.Development of Therapeutic dsP21-322 for Cancer Treatment.Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer.Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.
P2860
Q26824914-15DF7BB6-DD71-44DD-AB2F-D8860CBD08FCQ27687617-3715D077-2736-4567-ADF9-428799B6752EQ33625843-A892DF2C-5320-4C33-B03E-A95813DCD5EDQ33681531-FBE581A4-EF71-4892-BD22-AE8600BEEE4FQ34293651-B6E08E05-EBC8-45DF-86F9-9D172E919429Q34409699-A0CA2906-89B0-4D82-B4E1-F08C73C0FC95Q34452808-1CBD1348-5A7C-4D57-BE23-8F9FA2B70583Q34785672-D13E461E-99C7-44D7-9148-CBFABF843EC7Q34789701-46011F92-FE30-4046-AF3B-5B61BF85E249Q34994521-CF147806-5BF2-4C6F-B009-F3E9A43A1649Q35022673-4361B9D0-A948-4742-A8B5-86CB1114BB56Q35162535-0AB47300-3B74-4BF5-AEB6-22EEF8657BF2Q35307851-1EEE70D4-F257-431D-898E-639984E75240Q35637342-B64B56C6-FCD2-4316-900D-FD0DED0C08B9Q36147934-E75C279E-AF49-4EA4-B3C5-2E277CAFB42DQ36635881-2FDB4D40-8E15-46EA-B68F-6877F9E0531AQ37134623-027A92FA-FD45-46AF-A94F-C2B66C40AF94Q37249063-B1764AC9-39DB-4BA7-8FBE-5FD043AFD223Q37270994-7C500E37-4C94-492B-82D6-9A4BFF143E4AQ37283563-DB281603-F7C9-4C98-8954-BCBC9331547EQ37371047-B7B6A6FB-2C78-4597-9DDC-E5FABB17EFF6Q37642786-66DD1BC8-6D44-42AD-A431-2AF916486D4AQ37676223-1944A020-24E1-47B7-800A-2AD670E6B45AQ37944437-EF9C295C-37ED-4678-8338-B987864DB88CQ38075592-926B0103-8519-430D-BCF2-49765D34ED07Q38226663-4FED38C3-1CE2-4F97-8CF6-93BE02C4FE14Q38633884-361A828F-A9DF-425E-802B-FD4A7AFA5C7EQ38653106-575D48FB-2AA3-4909-8E90-6B0ABBF91618Q38741837-02894566-38BB-4224-89DA-FEC7979915EBQ38941125-5694CE7C-CC59-4F7D-BD41-4F96215A7FB3Q38968280-611646D5-F1F0-4613-81F6-ADC2CD1D0A1FQ39040360-1FAE768D-4E70-47AA-9837-02C998548A0FQ39127465-974A783D-62A1-42A1-A62B-C0CFCAE6E2A3Q39284112-7761DB9E-2B13-4E6B-A5B6-36F4F62D135CQ39390094-2C4F5948-2129-4504-9DE8-C435BE57EF48Q39390652-E36EDCF8-6C51-41DA-8709-6F05F025E168Q39398234-EE2CD579-0491-442B-9E82-0538A5FBADE9Q39539512-73D03526-7B86-4145-B7D0-4B16E7473FEEQ39601528-4E92D468-0DC6-4000-9F63-5360884393C1Q39654910-2BEF7B20-C31B-4395-8758-3FC3F83A4FFA
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Intravesical treatments of bladder cancer: review.
@ast
Intravesical treatments of bladder cancer: review.
@en
type
label
Intravesical treatments of bladder cancer: review.
@ast
Intravesical treatments of bladder cancer: review.
@en
prefLabel
Intravesical treatments of bladder cancer: review.
@ast
Intravesical treatments of bladder cancer: review.
@en
P2093
P2860
P1476
Intravesical treatments of bladder cancer: review
@en
P2093
Jessie L-S Au
M Guillaume Wientjes
Zancong Shen
P2860
P304
P356
10.1007/S11095-008-9566-7
P577
2008-03-28T00:00:00Z
2008-07-01T00:00:00Z